Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Arbutus Biopharma Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ABUS
Nasdaq
8731
https://www.arbutusbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Arbutus Biopharma Corp
Arbutus to Participate in Two Upcoming Investor Conferences
- Mar 8th, 2024 12:30 pm
Arbutus Biopharma Corporation (NASDAQ:ABUS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
- Mar 3rd, 2024 12:38 pm
Analysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue Forecasts
- Mar 2nd, 2024 12:29 pm
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript
- Mar 1st, 2024 1:17 pm
Q4 2023 Arbutus Biopharma Corp Earnings Call
- Mar 1st, 2024 4:14 am
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
- Feb 29th, 2024 1:40 pm
Arbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical Trials
- Feb 29th, 2024 12:52 pm
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
- Feb 29th, 2024 12:30 pm
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
- Feb 15th, 2024 12:30 pm
The past three years for Arbutus Biopharma (NASDAQ:ABUS) investors has not been profitable
- Feb 2nd, 2024 3:29 pm
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
- Jan 8th, 2024 12:30 pm
Institutions own 30% of Arbutus Biopharma Corporation (NASDAQ:ABUS) shares but individual investors control 32% of the company
- Jan 1st, 2024 11:21 am
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
- Nov 9th, 2023 9:24 pm
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver MeetingĀ®
- Nov 9th, 2023 9:01 pm
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call Transcript
- Nov 9th, 2023 2:12 pm
Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week
- Nov 9th, 2023 10:10 am
Arbutus to Present at Jefferies London Healthcare Conference
- Nov 8th, 2023 12:30 pm
Q3 2023 Arbutus Biopharma Corp Earnings Call
- Nov 8th, 2023 6:16 am
Arbutus Biopharma Corp (ABUS) Reports Q3 2023 Financial Results
- Nov 7th, 2023 1:05 pm
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 7th, 2023 12:30 pm
Scroll